Irish pharmaceutical company Galen has been granted marketing approval for a new delivery system for hormone replacement therapy (HRT).
The licence follows the approval letter Galen received in January.
The system can be used to deliver oestrogen for the relief of post-menopausal symptoms.
Mr Roger Boissonneault, chief executive of Galen, said today: "Our regulatory submissions are progressing well for the rest of Europe and the US and we look forward to updating the market on these developments in the coming months."
Galen shares are trading 12p higher at £7.80 on the London stock exchange this morning.
